Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Apotex

- PMLiVE

GSK signs agreement with Protas to streamline clinical trials

The new three-year agreement builds on an existing two-year relationship

- PMLiVE

Sandoz partners with Samsung Bioepis to develop up to five biosimilars

The agreement will expand the pipeline and builds on an existing partnership

- PMLiVE

Sandoz appoints Armin Metzger as President of new global unit

Metzger was most recently Executive VP, Chief Technical Operations Officer at Ferring Pharmaceuticals

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

- PMLiVE

GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults

RSV affects approximately 64 million people around the world each year

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

Sandoz launches first and only multiple sclerosis biosimilar in US

The treatment is FDA-approved to treat MS and Crohn’s disease

- PMLiVE

Sandoz to acquire Just-Evotec Biologics to strengthen biosimilar development and manufacturing capabilities

Acquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity

- PMLiVE

GSK’s Blenrep approved by FDA for multiple myeloma

Approval supported by positive results from phase 3 trial

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

- PMLiVE

GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

The decision means that eligible patients in England will be the first in the world to access the combination

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links